TEVA Pharmaceuticals: CONFIDENCE Study

What is the CONFIDENCE Study?

CONFIDENCE Research Study: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone® (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily

Why is this study being done?

The purpose of this study is to compare patient medication satisfaction between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) groups.

After 6 months of either treatment assignment, all subjects will enter the 6 month extension phase where all subjects will receive Copaxone 40 mg/mL three time a week (TIW). Study participation is 12 months in total and completely voluntary.

We are looking for adults who are at least 18 years of age or older with Relapsing remitting Multiple Sclerosis to participate in this 12 month research study.

Qualified participants will receive:

• Study-related medical evaluations

• Study-related investigational medications

• Compensated for time and travel may be provided

Study Investigators: Dr. Teresa DeAngelis and Dr. Richard Blanck

ClinicalTrials.gov Identifier: NCT02499900

Link for more information: https://clinicaltrials.gov/ct2/show/NCT02499900?term=copaxone&rank=19